Growth hormone-releasing peptides

Department of Internal Medicine, University of Turin, Italy.

Growth hormone-releasing peptides (GHRPs) are synthetic, non-natural peptides endowed with potent stimulatory effects on somatotrope secretion in animals and humans. They have no structural homology with GHRH and act via specific receptors present either at the pituitary or the hypothalamic level both in animals and in humans. The GHRP receptor has recently been cloned and, interestingly, it does not show sequence homology with other G-protein-coupled receptors known so far. This evidence strongly suggests the existence of a natural GHRP-like ligand which, however, has not yet been found. The mechanisms underlying the GHRP effect are still unclear. At present, several data favor the hypothesis that GHRPs could act by counteracting somatostatinergic activity both at the pituitary and the hypothalamic level and/or, at least partially, via a GHRH-mediated mechanism. However, the possibility that GHRPs act via an unknown hypothalamic factor (U factor) is still open. GHRP-6 was the first hexapeptide to be extensively studied in humans. More recently, a heptapeptide, GHRP-1, and two other hexapeptides, GHRP-2 and Hexarelin, have been synthesized and are now available for human studies. Moreover, non-peptidyl GHRP mimetics have been developed which act via GHRP receptors and their effects have been clearly demonstrated in animals and in humans in vivo. Among non-peptidyl GHRPs, MK-0677 seems the most interesting molecule. The GH-releasing activity of GHRPs is marked and dose-related after intravenous, subcutaneous, intranasal and even oral administration. The effect of GHRPs is reproducible and undergoes partial desensitization, more during continuous infusion, less during intermittent administration: in fact, prolonged administration of GHRPs increases IGF-1 levels both in animals and in humans. The GH-releasing effect of GHRPs does not depend on sex but undergoes age-related variations. It increases from birth to puberty, persists at a similar level in adulthood and decreases thereafter. By the sixth decade of life, the activity of GHRPs is reduced but it is still marked and higher than that of GHRH. The GH-releasing activity of GHRPs is synergistic with that of GHRH, is not affected by opioid receptor antagonists, such as naloxone, and is only blunted by inhibitory influences, including neurotransmitters, glucose, free fatty acids, gluco corticoids, recombinant human GH and even exogenous somatostatin, which are known to almost abolish the effect of GHRH. GHRPs maintain their GH-releasing effect in somatotrope hypersecretory states such as in acromegaly, anorexia nervosa and hyperthyroidism. On the other hand, their good GH-releasing activity has been shown in some but not in other somatotrope hyposecretory states. In fact, reduced GH responses after GHRP administration have been reported in idiopathic GH deficiency as well as in idiopathic short stature, in obesity and in hypothyroidism, while in patients with pituitary stalk disconnection or Cushing's syndrome the somatotrope responsiveness to GHRPs is almost absent. In short children an increase in height velocity has also been reported during chronic GHRP treatment. Thus, based on their marked GH-releasing effect even after oral administration, GHRPs offer their own clinical usefulness for treatment of some GH hyposecretory states.

This article has been cited by other articles:

				X. Qi, J. T. Reed, G. Wang, S. Han, E. W. Englander, and G. H. Greeley Jr. Ghrelin secretion is not reduced by increased fat mass during diet-induced obesity Am J Physiol Regulatory Integrative Comp Physiol, August 1, 2008; 295(2): R429 - R435. [Abstract] [Full Text] [PDF]

				W. Wei, X. Qi, J. Reed, J. Ceci, H.-Q. Wang, G. Wang, E. W. Englander, and G. H. Greeley Jr. Effect of chronic hyperghrelinemia on ingestive action of ghrelin Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2006; 290(3): R803 - R808. [Abstract] [Full Text] [PDF]

				J. Iqbal, Y. Kurose, B. Canny, and I. J. Clarke Effects of Central Infusion of Ghrelin on Food Intake and Plasma Levels of Growth Hormone, Luteinizing Hormone, Prolactin, and Cortisol Secretion in Sheep Endocrinology, January 1, 2006; 147(1): 510 - 519. [Abstract] [Full Text] [PDF]

				K. G. Brywe, A.-L. Leverin, M. Gustavsson, C. Mallard, R. Granata, S. Destefanis, M. Volante, H. Hagberg, E. Ghigo, and J. Isgaard Growth Hormone-Releasing Peptide Hexarelin Reduces Neonatal Brain Injury and Alters Akt/Glycogen Synthase Kinase-3{beta} Phosphorylation Endocrinology, November 1, 2005; 146(11): 4665 - 4672. [Abstract] [Full Text] [PDF]

				M. Groschl, H. G. Topf, J. Bohlender, J. Zenk, S. Klussmann, J. Dotsch, W. Rascher, and M. Rauh Identification of Ghrelin in Human Saliva: Production by the Salivary Glands and Potential Role in Proliferation of Oral Keratinocytes Clin. Chem., June 1, 2005; 51(6): 997 - 1006. [Abstract] [Full Text] [PDF]

				X.-B. Xu, J.-M. Cao, J.-J. Pang, R.-K. Xu, C. Ni, W.-L. Zhu, K. Asotra, M.-C. Chen, and C. Chen The Positive Inotropic and Calcium-Mobilizing Effects of Growth Hormone-Releasing Peptides on Rat Heart Endocrinology, November 1, 2003; 144(11): 5050 - 5057. [Abstract] [Full Text] [PDF]

				X. Qi, J. Reed, E. W. Englander, V. Chandrashekar, A. Bartke, and G. H. Greeley Jr. Evidence That Growth Hormone Exerts a Feedback Effect on Stomach Ghrelin Production and Secretion Experimental Biology and Medicine, October 1, 2003; 228(9): 1028 - 1032. [Abstract] [Full Text] [PDF]

				E. V. Dimaraki, C. A. Jaffe, C. Y. Bowers, P. Marbach, and A. L. Barkan Pulsatile and nocturnal growth hormone secretions in men do not require periodic declines of somatostatin Am J Physiol Endocrinol Metab, July 1, 2003; 285(1): E163 - E170. [Abstract] [Full Text] [PDF]

				H. Ariyasu, K. Takaya, H. Hosoda, H. Iwakura, K. Ebihara, K. Mori, Y. Ogawa, K. Hosoda, T. Akamizu, M. Kojima, et al. Delayed Short-Term Secretory Regulation of Ghrelin in Obese Animals: Evidenced by a Specific RIA for the Active Form of Ghrelin Endocrinology, September 1, 2002; 143(9): 3341 - 3350. [Abstract] [Full Text] [PDF]

				V. Bodart, M. Febbraio, A. Demers, N. McNicoll, P. Pohankova, A. Perreault, T. Sejlitz, E. Escher, R.L. Silverstein, D. Lamontagne, et al. CD36 Mediates the Cardiovascular Action of Growth Hormone-Releasing Peptides in the Heart Circ. Res., May 3, 2002; 90(8): 844 - 849. [Abstract] [Full Text] [PDF]

				M. Volante, E. AllIa, P. Gugliotta, A. Funaro, F. Broglio, R. Deghenghi, G. Muccioli, E. Ghigo, and M. Papotti Expression of Ghrelin and of the GH Secretagogue Receptor by Pancreatic Islet Cells and Related Endocrine Tumors J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1300 - 1308. [Abstract] [Full Text] [PDF]

				M. Papotti, P. Cassoni, M. Volante, R. Deghenghi, G. Muccioli, and E. Ghigo Ghrelin-Producing Endocrine Tumors of the Stomach and Intestine J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 5052 - 5059. [Abstract] [Full Text] [PDF]

				A. Garcia, C. V. Alvarez, R. G. Smith, and C. Dieguez Regulation of PIT-1 Expression By Ghrelin and GHRP-6 Through the GH Secretagogue Receptor Mol. Endocrinol., September 1, 2001; 15(9): 1484 - 1495. [Abstract] [Full Text] [PDF]

				R. G. Gondo, M. H. Aguiar-Oliveira, C. Y. Hayashida, S. P. A. Toledo, N. Abelin, M. A. Levine, C. Y. Bowers, A. H. O. Souza, R. M. C. Pereira, N. L. Santos, et al. Growth Hormone-Releasing Peptide-2 Stimulates GH Secretion in GH-Deficient Patients with Mutated GH-Releasing Hormone Receptor J. Clin. Endocrinol. Metab., July 1, 2001; 86(7): 3279 - 3283. [Abstract] [Full Text] [PDF]

				P. Cassoni, M. Papotti, C. Ghè, F. Catapano, A. Sapino, A. Graziani, R. Deghenghi, T. Reissmann, E. Ghigo, and G. Muccioli Identification, Characterization, and Biological Activity of Specific Receptors for Natural (Ghrelin) and Synthetic Growth Hormone Secretagogues and Analogs in Human Breast Carcinomas and Cell Lines J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1738 - 1745. [Abstract] [Full Text]

				E. Arvat, M. Maccario, L. Di Vito, F. Broglio, A. Benso, C. Gottero, M. Papotti, G. Muccioli, C. Dieguez, F. F. Casanueva, et al. Endocrine Activities of Ghrelin, a Natural Growth Hormone Secretagogue (GHS), in Humans: Comparison and Interactions with Hexarelin, a Nonnatural Peptidyl GHS, and GH-Releasing Hormone J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1169 - 1174. [Abstract] [Full Text]

				L. Gianotti, M. Maccario, F. Lanfranco, J. Ramunni, L. Di Vito, S. Grottoli, E. E. Muller, E. Ghigo, and E. Arvat Arginine Counteracts the Inhibitory Effect of Recombinant Human Insulin-Like Growth Factor I on the Somatotroph Responsiveness to Growth Hormone-Releasing Hormone in Humans J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3604 - 3608. [Abstract] [Full Text]

				M. Papotti, C. Ghè, P. Cassoni, F. Catapano, R. Deghenghi, E. Ghigo, and G. Muccioli Growth Hormone Secretagogue Binding Sites in Peripheral Human Tissues J. Clin. Endocrinol. Metab., October 1, 2000; 85(10): 3803 - 3807. [Abstract] [Full Text]

				N. Shah, W. S. Evans, C. Y. Bowers, and J. D. Veldhuis Oral Estradiol Administration Modulates Continuous Intravenous Growth Hormone (GH)-Releasing Peptide-2-Driven GH Secretion in Postmenopausal Women J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2649 - 2659. [Abstract] [Full Text]

				V. Bodart, J. F. Bouchard, N. McNicoll, E. Escher, P. Carriere, E. Ghigo, T. Sejlitz, M. G. Sirois, D. Lamontagne, and H. Ong Identification and Characterization of a New Growth Hormone-Releasing Peptide Receptor in the Heart Circ. Res., October 29, 1999; 85(9): 796 - 802. [Abstract] [Full Text] [PDF]

				E. E. Muller, V. Locatelli, and D. Cocchi Neuroendocrine Control of Growth Hormone Secretion Physiol Rev, April 1, 1999; 79(2): 511 - 607. [Abstract] [Full Text] [PDF]

				E. Ghigo, L. Gianotti, E. Arvat, J. Ramunni, M. R. Valetto, F. Broglio, M. Rolla, F. Cavagnini, and E. E. Müller Effects of Recombinant Human Insulin-Like Growth Factor I Administration on Growth Hormone (GH) Secretion, Both Spontaneous and Stimulated by GH-Releasing Hormone or Hexarelin, a Peptidyl GH Secretagogue, in Humans J. Clin. Endocrinol. Metab., January 1, 1999; 84(1): 285 - 290. [Abstract] [Full Text]

				A. Giustina and J. D. Veldhuis Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human Endocr. Rev., December 1, 1998; 19(6): 717 - 797. [Abstract] [Full Text]

				E. Arvat, R. Giordano, J. Ramunni, G. Arnaldi, A. Colao, R. Deghenghi, G. Lombardi, F. Mantero, F. Camanni, and E. Ghigo Adrenocorticotropin and Cortisol Hyperresponsiveness to Hexarelin in Patients with Cushing's Disease Bearing a Pituitary Microadenoma, But Not in Those with Macroadenoma J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4207 - 4211. [Abstract] [Full Text]

				P. F. Catalina, F. Mallo, M. A. Andrade, R. V. García-Mayor, and C. Diéguez Growth Hormone (GH) Response to GH-Releasing Peptide-6 in Type 1 Diabetic Patients with Exaggerated GH-Releasing Hormone-Stimulated GH Secretion J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3663 - 3667. [Abstract] [Full Text]

				D. F. Carmignac, P. A. Bennett, and I. C. A. F. Robinson Effects of Growth Hormone Secretagogues on Prolactin Release in Anesthetized Dwarf (dw/dw) Rats Endocrinology, August 1, 1998; 139(8): 3590 - 3596. [Abstract] [Full Text] [PDF]

				D. Micic, V. Popovic, M. Doknic, D. Macut, C. Dieguez, and F. F. Casanueva Preserved Growth Hormone (GH) Secretion in Aged and Very Old Subjects after Testing with the Combined Stimulus GH-Releasing Hormone plus GH-Releasing Hexapeptide-6 J. Clin. Endocrinol. Metab., July 1, 1998; 83(7): 2569 - 2572. [Abstract] [Full Text]

				V. Bodart, M. Febbraio, A. Demers, N. McNicoll, P. Pohankova, A. Perreault, T. Sejlitz, E. Escher, R.L. Silverstein, D. Lamontagne, et al. CD36 Mediates the Cardiovascular Action of Growth Hormone-Releasing Peptides in the Heart Circ. Res., May 3, 2002; 90(8): 844 - 849. [Abstract] [Full Text] [PDF]